Additional file 3 of An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Stringer-Reasor, Erica M.; May, Jori E.; Olariu, Eva; Caterinicchia, Valerie; Li, Yufeng; Chen, Dongquan; Della Manna, Deborah L.; Rocque, Gabrielle B.; Vaklavas, Christos; Falkson, Carla I.; Nabell, Lisle M.; Acosta, Edward P.; Forero-Torres, Andres; Yang, Eddy S.

doi:10.6084/m9.figshare.14168149.v1

13058_2021_1408_MOESM3_ESM.pdf (295.04 kB)

Additional file 3 of An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

journal contribution

posted on 2021-03-05, 04:34 authored by Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang

Additional file 3. Independent Pathway Analysis. This file contains the major pathways found from IPA.

Funding

AACR-TNBC Foundation Grant Scariot Foundation

History

Usage metrics

Keywords

PARP inhibitors DNA repair Synthetic lethality Targeted therapy Triple-negative breast cancer

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 3 of An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Funding

AACR-TNBC Foundation Grant Scariot Foundation

History

Usage metrics

Categories

Keywords

Licence

Exports